Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$160.32 USD

160.32
900,685

+0.63 (0.40%)

Updated Oct 9, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Fortive Plans to Buy Johnson & Johnson's Sterilization Unit

Fortive (FTV) is likely to enter the medical sterilization and disinfection market with its intended purchase of Johnson & Johnson's Sterilization business.

    J&J Receives Buyout Offer for Sterilization Products Unit

    Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.

      3 Biotech Stocks Up in the Past Month on Industry Turnaround

      We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.

        Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis

        The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.

          AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint

          AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.

            Novartis Gets Approval for Remicade Biosimilar in Europe

            Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.

              Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis

              Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.

                Sweta Killa headshot

                Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?

                Smart Beta ETF report for FDRR

                  Sweta Killa headshot

                  Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?

                  Style Box ETF report for PFM

                    Sanghamitra Saha headshot

                    Will China Erase Birth Limits? Stocks & ETFs to Watch

                    Reports of a possible end to China's four-decade-old birth restriction may boost these stocks and ETFs.

                      Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

                      Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

                        Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?

                        Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

                          Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

                            Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down

                            Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.

                              Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?

                              Both Merck and Pfizer reported upbeat first-quarter results on May 1

                                VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

                                VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

                                  Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y

                                  Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.

                                    What's in the Cards for Geron (GERN) This Earnings Season?

                                    With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

                                      Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook

                                      Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.

                                        Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat

                                        Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.

                                          Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?

                                          Smart Beta ETF report for FDRR

                                            Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales

                                            Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.

                                              AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains

                                              AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                                                Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses

                                                Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.

                                                  Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?

                                                  Style Box ETF report for PFM